Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)

被引：1
|
作者：
Xu, J. [1 ]
Shen, L. [2 ]
Bai, C. [3 ]
Li, J. [2 ]
Zhou, Z. [4 ]
Yu, X. [5 ]
Li, Z. [6 ]
Li, E. [7 ]
Yuan, X. [8 ]
Chi, Y. [9 ,10 ]
Yin, Y. [11 ]
Lou, W. [12 ]
Xu, N. [13 ]
Bai, Y. [14 ]
Zhang, T. [15 ]
Xiu, D. [16 ]
Wang, X. [17 ]
Li, J. [2 ]
Fan, S.
Su, W. [18 ]
机构：
[1] Gen Hosp Peoples Liberat Army, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Dept GI Oncol, Beijing, Peoples R China
[3] Peking Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China
[4] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Gastr Surg,Canc Ctr, Guangzhou, Guangdong, Peoples R China
[5] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai, Peoples R China
[6] Sichuan Univ, West China Hosp, Dept Abdominal Oncol, Chengdu, Sichuan, Peoples R China
[7] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Shaanxi, Peoples R China
[8] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Hubei, Peoples R China
[9] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China
[10] Peking Union Med Coll, Beijing, Peoples R China
[11] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China
[12] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China
[13] Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
[14] Harbin Med Univ Canc Hosp, Dept Gastrointestinal Oncol, Harbin, Peoples R China
[15] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan, Hubei, Peoples R China
[16] Peking Univ, Hosp 3, Dept Gen Surg, Beijing, Peoples R China
[17] Shandong Univ, Qilu Hosp, Dept Med Oncol, Jinan, Peoples R China
[18] Hutchison MediPharma Ltd, Clin Dept & Regulatory Affairs, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1369
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1156O
引用
收藏
页码：S770 / S770
页数：1
相关论文
共 50 条
  • [1] Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)
    Li, Jiarui
    Cheng, Yuejuan
    Bai, Chunmei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Chi, Yihebali
    Yu, Xianjun
    Li, Enxiao
    Xu, Nong
    Liu, Tianshu
    Lou, Wenhui
    Bai, Yuxian
    Yuan, Xianglin
    Wang, Xiuwen
    Yuan, Ying
    Chen, Jia
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    EUROPEAN JOURNAL OF CANCER, 2022, 169 : 1 - 9
  • [2] Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
    Xu, Jianming
    Shen, Lin
    Zhou, Zhiwei
    Li, Jie
    Bai, Chunmei
    Chi, Yihebali
    Li, Zhiping
    Xu, Nong
    Li, Enxiao
    Liu, Tianshu
    Bai, Yuxian
    Yuan, Ying
    Li, Xingya
    Wang, Xiuwen
    Chen, Jia
    Ying, Jieer
    Yu, Xianjun
    Qin, Shukui
    Yuan, Xianglin
    Zhang, Tao
    Deng, Yanhong
    Xiu, Dianrong
    Cheng, Ying
    Tao, Min
    Jia, Ru
    Wang, Wei
    Li, Jing
    Fan, Songhua
    Peng, Mengye
    Su, Weiguo
    LANCET ONCOLOGY, 2020, 21 (11): : 1500 - 1512
  • [3] Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).
    Yu, Xianjun
    Xu, Jianming
    Shen, Lin
    Bai, Chunmei
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Li, Enxiao
    Yuan, Xianglin
    Chi, Yihebali
    Yin, Yongmei
    Lou, Wenhui
    Xu, Nong
    Bai, Yuxian
    Zhang, Tao
    Xiu, Dianrong
    Wang, Xiuwen
    Guan, Sha
    Xu, Qian
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extra pancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double- blind, phase III trials (SANET-p and SANET-ep)' (vol 169, pg 1, 2022)
    Li, Jiarui
    Cheng, Yuejuan
    Bai, Chunmei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Chi, Yihebali
    Yu, Xianjun
    Li, Enxiao
    Xu, Nong
    Liu, Tianshu
    Lou, Wenhui
    Bai, Yuxian
    Yuan, Xianglin
    Wang, Xiuwen
    Yuan, Ying
    Chen, Jia
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    EUROPEAN JOURNAL OF CANCER, 2023, 178 : 247 - 248
  • [5] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III TRIAL OF EVEROLIMUS IN PATIENTS WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET) (RADIANT-3)
    Yao, J. C.
    Shah, M. H.
    Ito, T.
    Lombard-Bohas, C.
    Wolin, E. M.
    Van Cutsem, E.
    Sachs, C.
    Hoosen, S.
    Lincy, J.
    Hobday, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 4 - 5
  • [6] Updated Survival and Safety Data From RADIANT-3-a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Trial of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET)
    Lombard-Bohas, C.
    Van Cutsem, E.
    Capdevila, J.
    de Vries, E. G. E.
    Tomassetti, P.
    Lincy, J.
    Winkler, R. E.
    Hobday, T.
    Pommier, R.
    Yao, J. C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S459 - S459
  • [7] Health-Related Quality-of-Life Analysis of Surufatinib Versus Placebo for Advanced Neuroendocrine Tumors: Pooled Results From Two Phase 3 Studies (SANET-p and SANET-ep)
    Bai, Chunmei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Chi, Yihebali
    Yu, Xianjun
    Li, Enxiao
    Xu, Nong
    Liu, Tianshu
    Lou, Wenhui
    Bai, Yuxian
    Yuan, Xianglin
    Wang, Xiuwen
    Yuan, Ying
    Chen, Jia
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    PANCREAS, 2022, 51 (03) : E39 - E39
  • [8] Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3)
    Shah, M. H.
    Ito, T.
    Lombrd-Bohas, C.
    Wolin, E. M.
    Van Cutsem, E.
    Sachs, C.
    Winkler, R. E.
    Lincy, J.
    Hobday, T. J.
    Yao, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [9] Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3)
    Strosberg, J. R.
    Lincy, J.
    Winkler, R. E.
    Wolin, E. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer
    Vervenne, W.
    Bennouna, J.
    Humblet, Y.
    Gill, S.
    Moore, M. J.
    Van Laethem, J.
    Shang, A.
    Cosaert, J.
    Verslype, C.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345